Prostate cancer: no/incomplete PSA testing linked to high-risk disease in older men

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

 

  • Almost half of older men undergoing radiotherapy for prostate cancer had no/incomplete prostate-specific antigen (PSA) testing. 
  • No/incomplete PSA testing was associated with high-risk disease.

 

Why this matters

  • Consider screening healthy older men who are likely to benefit from early detection and treatment.

Key results

  • 54.0% underwent PSA testing with appropriate follow-up biopsy, 26.3% underwent PSA testing without biopsy, and 19.7% received no PSA testing. 
  • Odds of PSA testing decreased by 20% with each additional year of age (P<.001). 
  • PSA testing rates did not significantly differ before vs after the 2008 US Preventive Services Task Force recommendations (P=.91). 
  • Men without PSA testing were more likely to be diagnosed with higher stage disease (P=.002). 
  • PSA-tested cohort was significantly more likely to be diagnosed with low-grade disease (Grade group [GG] 1; 42.6% vs 16.7%) and less likely to be diagnosed with high-grade disease (GG4-5; 19.0% vs 41.3%). 
  • 51.6% of untested men were diagnosed with high-risk disease vs 23.0% of tested men. 
  • Untested men had higher odds of being diagnosed with high-risk disease (OR, 3.39; P<.001).

Study design

  • Retrospective review of records from 1993 to 2014. 
  • Funding: None specified.

Limitations

  • Lack of comorbidity data. 
  • Population derived from a tertiary referral center.